We are thrilled to announce that Recursion is setting a new gold standard for the industry with the release of ...

She previously led clinical development programs in cystic fibrosis and multiple sclerosis at Vertex and Biogen ... the ability to implement business plans, forecasts, and other expectations in the ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

A general view of the Centers for Disease Control and Prevention (CDC) headquarters in Atlanta, Georgia September 30, 2014. REUTERS/Tami Chappell/File Photo The number of sexually transmitted ...

'We're quite optimistic that it would still be a good year for PLDT this year, but we have to do better next year,' says Manuel Pangilinan ...

© 2024 BBC. The BBC is not responsible for the content of external sites. Read about our approach to external linking.